An induced pluripotent stem cell-mediated and integration-free factor VIII expression system

Area of Science:

• Gene Therapy
• Stem Cell Biology
• Genetics

Background:

• Human artificial chromosomes (HACs) offer stable episomal maintenance and large gene-carrying capacity for gene therapy.
• Induced pluripotent stem (iPS) cells hold potential for patient-specific gene therapy due to their regenerative capabilities.
• Sendai virus (SeV) vectors efficiently generate iPS cells without integrating into the host genome.

Purpose of the Study:

• To develop an integration-free coagulation factor VIII (FVIII) expression system for hemophilia A treatment.
• To utilize iPS cells and HAC vectors for a safer, non-integrating gene therapy approach.

Main Methods:

• Constructed a HAC vector (PF4-FVIII-HAC) containing multiple human FVIII genes under a megakaryocyte-specific promoter.
• Introduced the PF4-FVIII-HAC into SeV-generated iPS cells from a hemophilia A mouse model.
• Differentiated iPS cells carrying the PF4-FVIII-HAC into megakaryocytes/platelets in vitro.

Main Results:

• The PF4-FVIII-HAC was successfully introduced and maintained in iPS cells.
• In vitro differentiation led to the expression of FVIII from the introduced HAC vector.
• Demonstrated successful FVIII expression in a cellular model for hemophilia A.

Conclusions:

• Developed a novel iPS cell-mediated, integration-free FVIII expression system using SeV and HAC vectors.
• This system shows promise as a safer gene and cell therapy strategy for hemophilia A.
• Highlights the potential of combining iPS cells and non-integrating HAC vectors for genetic disorders.